Bruker Co. (NASDAQ:BRKR) CEO Frank H. Laukien Purchases 2,608 Shares

Bruker Co. (NASDAQ:BRKR - Get Free Report) CEO Frank H. Laukien purchased 2,608 shares of the company's stock in a transaction dated Friday, June 6th. The shares were acquired at an average price of $38.36 per share, with a total value of $100,042.88. Following the transaction, the chief executive officer now owns 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. The trade was a 0.01% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Bruker Trading Up 2.4%

Shares of BRKR traded up $0.91 during mid-day trading on Monday, reaching $39.21. The company's stock had a trading volume of 2,037,223 shares, compared to its average volume of 1,613,612. Bruker Co. has a 52 week low of $34.10 and a 52 week high of $72.94. The stock has a market cap of $5.94 billion, a PE ratio of 51.59, a P/E/G ratio of 2.16 and a beta of 1.16. The company's fifty day moving average price is $38.16 and its two-hundred day moving average price is $48.43. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. The business had revenue of $801.40 million during the quarter, compared to the consensus estimate of $763.83 million. During the same period in the previous year, the firm posted $0.53 earnings per share. The firm's revenue for the quarter was up 11.0% on a year-over-year basis. On average, analysts predict that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Monday, June 16th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date is Monday, June 16th. Bruker's dividend payout ratio (DPR) is presently 38.46%.

Wall Street Analyst Weigh In

BRKR has been the topic of a number of recent analyst reports. UBS Group lowered their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Stifel Nicolaus decreased their price target on shares of Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a report on Thursday, May 8th. Guggenheim restated a "buy" rating on shares of Bruker in a research report on Monday, February 24th. Citigroup lowered shares of Bruker from a "strong-buy" rating to a "hold" rating and cut their target price for the stock from $50.00 to $40.00 in a research report on Thursday, May 22nd. Finally, The Goldman Sachs Group reduced their target price on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $56.22.

Hedge Funds Weigh In On Bruker

Institutional investors and hedge funds have recently bought and sold shares of the stock. London Co. of Virginia lifted its position in Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock valued at $245,820,000 after purchasing an additional 1,843,294 shares during the last quarter. Sculptor Capital LP raised its holdings in Bruker by 484.1% during the 4th quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock valued at $100,476,000 after buying an additional 1,420,569 shares during the last quarter. FIL Ltd boosted its position in Bruker by 262.3% during the 4th quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock valued at $114,978,000 after buying an additional 1,420,102 shares during the period. Steadfast Capital Management LP bought a new stake in Bruker in the 4th quarter worth $63,997,000. Finally, Norges Bank purchased a new stake in Bruker in the fourth quarter worth $63,378,000. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.